Board Meeting on 27 Oct 2026 to consider Q2 FY27 financial results

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

MOREPENLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.2%Reaction day

₹118.55

prior close

₹115.25

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.3%+6.5% vs market

Pharmaceuticals peers, median of 170sector-1.6%+5.8% vs sector

On the reaction day the stock moved 6.5 pts more than Nifty Microcap 250 and 5.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.2

10m

+1.3

15m

+3.1

30m

+2.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.2-2.3+6.5-1.6+5.8

Next day

+6.7-1.9+8.6-0.5+7.2

+11.6-0.2+11.9+1.5+10.1

+5.9-0.2+6.1+2.5+3.5

+0.6+0.5+0.2+2.7-2.1

-4.4-2.0-2.4+1.6-5.9

-13.7-0.3-13.4+1.5-15.2

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Morepen Laboratories has informed exchanges that its Board of Directors will meet on 27 October 2026 to consider and approve the unaudited standalone and consolidated financial results for Q2 and H1 FY27 (quarter and half year ended 30 September 2026). The trading window for designated persons and their immediate relatives will remain closed until 29 October 2026, in line with insider trading rules.

Likely market impact

Investors should watch for Q2 FY27 results on 27 Oct; possible price movement around the announcement as trading window is closed.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹746.5 Cr	₹411.6 Cr	+81.4%
Operating profit	₹107.9 Cr	₹15.23 Cr	+608.0%
Profit after tax	₹88.89 Cr	₹40.87 Cr	+117.5%
EBITDA margin	16.5%	13.7%	+2.8 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.